Investment Trusts

BB Biotech AG

BION:SWX

BB Biotech AG

Actions
  • Price (CHF)39.80
  • Today's Change0.300 / 0.76%
  • Shares traded23.63k
  • 1 Year change+6.42%
  • Beta1.1125
Data delayed at least 15 minutes, as of Nov 11 2024 10:15 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Key statistics

As of last trade, BB Biotech AG (BION:SWX) traded at 39.80, 12.27% above the 52 week low of 35.45 set on Oct 04, 2024.
52-week range
Today
35.45Oct 04 202449.80Feb 23 2024
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Shares outstanding55.40m
Market cap2.19bn CHF
Total assets2.57bn CHF
Total expense ratio1.43%
High40.00
Low39.70
Previous close39.50
Average volume107.53k
YTD Change-6.90%
Beta1.1125
Diluted NAV (est)46.40
Diluted NAV (last pub)46.40
Premium/Discount--
Net Gearing0.00%
Annual div (ADY)2.00
CHF
Annual div yield (ADY)5.06%
Div ex-dateMar 25 2024
Div pay-dateMar 27 2024
Data delayed at least 15 minutes, as of Nov 11 2024 10:15 GMT.
More ▼

Board of Directors

1/4

Dr. Erich Hunziker, Chairman

2/4

Dr. Clive Meanwell, Vice Chairman

3/4

Prof. Dr. Dr. Klaus Strein, Member

4/4

Dr. Thomas von Planta, Member

Contact

BB Biotech AG
Schwertstrasse 6
8200 Schaffhausen/Switzerland

T: +41 52 624 08 45
E: info(at)bbbiotech.com
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.